NASDAQ: TILInstil Bio Inc Stock
$10.64+0.23 (+2.21%)
Updated Apr 19, 2024
TIL Price
$10.64
Fair Value Price
N/A
Market Cap
$69.20M
52 Week Low
$6.07
52 Week High
$14.00
P/E
-0.44x
P/B
0.31x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$156.09M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.44
Operating Cash Flow
-$82M
Beta
1.54
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TIL Overview
Instil Bio Incorporated is a biopharmaceutical company developing cancer therapies. Its Tumor Infiltrating Lymphocyte (TIL) product candidates in pipeline include ITIL-168 for as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer, and ITIL-306 for gynecological, non-small cell lung cancer, renal caner, and others. Imstil Bio was incorporated in 2018 and is headquartered in Dallas, TX.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TIL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TIL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TIL is good value based on its book value relative to its share price (0.31x), compared to the US Biotechnology industry average (5.74x)
P/B vs Industry Valuation
TIL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TIL due diligence checks available for Premium users.
Be the first to know about important TIL news, forecast changes, insider trades & much more!
TIL News
Valuation
TIL fair value
Fair Value of TIL stock based on Discounted Cash Flow (DCF)
Price
$10.64
Fair Value
$0.00
Overvalued by
1,095,209.19%
TIL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TIL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.44x
Industry
15.81x
Market
40.51x
TIL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
5.74x
TIL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TIL's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.9M
Profit Margin
0%
TIL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$325.6M
Liabilities
$99.8M
Debt to equity
0.44
TIL's short-term assets ($160.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TIL's short-term assets ($160.76M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TIL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.4M
Investing
$14.0M
Financing
$0.0
TIL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TIL vs Biotech Stocks
Instil Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.